A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2001
12/01/2001	CA2347276A1 I g e-dependent histamine-releasing factor (hrf) receptor, hrf-binding peptides and nucleic acids encoding the same, and uses thereof
11/2001
11/30/2001	CA2348847A1 New isoxazole-sulfonamide endothelin antagonists
11/29/2001	WO2001090758A2 Diagnosis of alzheimer's disease ldl receptor protein-1
11/29/2001	WO2001090371A1 Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome)
11/29/2001	WO2001090359A2 G-protein coupled receptors
11/29/2001	WO2001090334A2 Drug metabolizing enzymes
11/29/2001	WO2001090315A2 Production of neurons from stem cells
11/29/2001	WO2001090191A2 ANTIBODIES CAPABLE TO SELECTIVELY DETECT PRION PrPSc ISOFORMS
11/29/2001	WO2001090189A2 G-protein coupled receptor org3.
11/29/2001	WO2001090182A2 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
11/29/2001	WO2001090156A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use
11/29/2001	WO2001090155A2 Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
11/29/2001	WO2001090148A2 Neurotransmitter transporters
11/29/2001	WO2001090142A2 FULL LENGTH HUMAN HCN1 Ih CHANNEL SUBUNIT AND VARIANTS
11/29/2001	WO2001090139A2 A ligand for enhancing oral and cns delivery of biological agents
11/29/2001	WO2001090129A2 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
11/29/2001	WO2001090110A1 Macrolides
11/29/2001	WO2001090109A1 Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
11/29/2001	WO2001090108A1 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
11/29/2001	WO2001090106A2 Tryasolyl tropane derivatives as ccr5 modulators
11/29/2001	WO2001090104A2 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
11/29/2001	WO2001090103A2 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
11/29/2001	WO2001090101A1 Arylmethylamine derivatives for use as tryptase inhibitors
11/29/2001	WO2001090100A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
11/29/2001	WO2001090094A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090093A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090092A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090091A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090090A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090086A1 A polymorph of 5-(4-aminosulfonyl-3-fluorophenyl)-4-cyclohexyl-2-methyloxazole
11/29/2001	WO2001090084A1 Benzodiazepine derivatives as app modulators
11/29/2001	WO2001090083A1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
11/29/2001	WO2001090077A1 Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
11/29/2001	WO2001090076A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
11/29/2001	WO2001090070A2 Caspase inhibitors and uses thereof
11/29/2001	WO2001090069A1 Novel calcium receptor active molecules and method for preparing same
11/29/2001	WO2001090068A2 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
11/29/2001	WO2001090063A2 Prodrug of an ice inhibitor
11/29/2001	WO2001090057A1 Sulfonamide derivatives
11/29/2001	WO2001090056A1 Sulfonamide derivatives
11/29/2001	WO2001090052A1 Cyclic amino acid derivatives useful as pharmaceutical agents
11/29/2001	WO2001090047A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001	WO2001089583A2 Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
11/29/2001	WO2001089570A2 Combination of growth hormone secretagogues and antidepressants
11/29/2001	WO2001089569A1 Combinations of enzyme inhibitor-containing preparations and the use thereof
11/29/2001	WO2001089568A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/29/2001	WO2001089558A2 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
11/29/2001	WO2001089550A2 Use of ciliary neurotrophic factor
11/29/2001	WO2001089544A1 Antimigraine combination comprising sapindus and emblica extracts
11/29/2001	WO2001089538A2 Apoptotic entities for use in treatment of endothelium dysfunction disorders
11/29/2001	WO2001089537A2 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
11/29/2001	WO2001089536A2 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
11/29/2001	WO2001089530A2 Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
11/29/2001	WO2001089524A1 Method of promoting smoking cessation
11/29/2001	WO2001089521A1 Medicinal compositions containing thiophene derivatives
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089507A1 NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
11/29/2001	WO2001089500A2 Agents and methods for increasing brain chaperonin levels
11/29/2001	WO2001089498A2 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
11/29/2001	WO2001089497A2 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
11/29/2001	WO2001089490A1 Dosage of transdermal delivery systems
11/29/2001	WO2001089489A2 Transdermal application of active agents directly via the carotid artery
11/29/2001	WO2001089474A2 O/w emulsion
11/29/2001	WO2001089453A2 Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differential cns receptor activity and behavior
11/29/2001	WO2001089451A2 Protease inhibitors
11/29/2001	WO2001089450A2 Treating musculoskeletal disorders using lp85 and analogs thereof
11/29/2001	WO2001089445A1 Blister package for topiramate tablets
11/29/2001	WO2001089319A2 Tryptophan source from plants and uses therefor
11/29/2001	WO2001070695A8 Pyridine derivatives as inhibitors of p38
11/29/2001	WO2001062284A3 Novel method for down-regulation of amyloid
11/29/2001	WO2001060835A8 Purine derivatives
11/29/2001	WO2001049674A3 Glycosidase inhibitors and preparation thereof
11/29/2001	WO2001049305A3 Process for obtaining thylakoids from plants, pure thylakoids and use thereof
11/29/2001	WO2001042471A8 Polypeptides and polynucleotides encoding same
11/29/2001	WO2001041756A8 Method and composition for treatment of ischemic neuronal reperfusion injury
11/29/2001	WO2001038566A3 Screening method for candidate drugs
11/29/2001	WO2001037816A3 Coating of tablet cores
11/29/2001	WO2001034095A8 A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t
11/29/2001	WO2001031007A3 Nucleic acid molecules derived from rat brain and programmed cell death models
11/29/2001	WO2001027304A3 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
11/29/2001	WO2001023590A3 22196, a novel human aminopeptidase
11/29/2001	WO2000073469A3 Protein kinases
11/29/2001	WO2000055159A3 Substituted aza-oxindole derivatives
11/29/2001	WO2000039114A3 Substituted oximes and hydrazones as neurokinin antagonists
11/29/2001	WO2000034258A3 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
11/29/2001	US20010047090 VANILREP1 polynucleotides and VANILREP1 polypeptides
11/29/2001	US20010047032 Polyhydroxyaromatic or polyhydroxyheteroaromatic compounds are useful for treating Alzheimer's disease, Parkinson's disease and Lewy body disease and others
11/29/2001	US20010047031 Heterocyclic compounds useful as NMDA receptor selective subtype blockers
11/29/2001	US20010047014 4-Benzyl-1-(2-(p-hydroxyphenoxy)ethyl)piperidine-3,4-diol; preparation from 1-(2-haloethoxy)-4-benzyloxybenzene and 4-benzylpiperidine-3,4-diol
11/29/2001	US20010047011 Preventing and treating motor neuron diseases such as ALS
11/29/2001	US20010047008 Allosteric adenosine receptor modulators
11/29/2001	US20010046993 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
11/29/2001	US20010046988 Especially treating fibromyalgia, chronic fatigue syndrome, psychogenic pain and chromic pain
11/29/2001	US20010046963 Inhibiting cyclooxygenase-2 biosynthesis and Nuclear factor kappa B synthesis; treatment of arthritis and Alzheimer's disease; administering in food
11/29/2001	US20010046962 Presynaptic neurotoxin such as botulinum toxin A
11/29/2001	US20010046959 Method of treating cancer with anti-neurotrophin agents
11/29/2001	US20010046519 Compositions for nasal administration
11/29/2001	US20010046490 Cell surface molecule-induced macrophage activation
11/29/2001	US20010046481 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
11/29/2001	DE10025949A1 Arzneimittel zur Bekämpfung von Atemdepression Medications to fight respiratory depression

1 ... 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 ... 1833